UK markets close in 3 hours 23 minutes
  • FTSE 100

    7,316.93
    +84.65 (+1.17%)
     
  • FTSE 250

    23,196.92
    +315.59 (+1.38%)
     
  • AIM

    1,194.47
    +14.44 (+1.22%)
     
  • GBP/EUR

    1.1771
    +0.0021 (+0.18%)
     
  • GBP/USD

    1.3250
    -0.0011 (-0.08%)
     
  • BTC-GBP

    38,525.27
    +1,701.61 (+4.62%)
     
  • CMC Crypto 200

    1,319.59
    +59.43 (+4.72%)
     
  • S&P 500

    4,591.67
    +53.24 (+1.17%)
     
  • DOW

    35,227.03
    +646.95 (+1.87%)
     
  • CRUDE OIL

    71.63
    +2.14 (+3.08%)
     
  • GOLD FUTURES

    1,784.50
    +5.00 (+0.28%)
     
  • NIKKEI 225

    28,455.60
    +528.23 (+1.89%)
     
  • HANG SENG

    23,983.66
    +634.28 (+2.72%)
     
  • DAX

    15,694.99
    +314.20 (+2.04%)
     
  • CAC 40

    7,018.88
    +153.10 (+2.23%)
     

Arix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Arix Bioscience PLC (ARIX)
08-Nov-2021 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

 

 

 

Arix Bioscience plc

Arix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference

 

LONDON, 8 November 2021: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that Mark Chin, Managing Director, is scheduled to participate in a virtual analyst-led fireside chat with Matthew Hose, Equity Research Analyst, at Jefferies London Healthcare Conference taking place in person and virtually from 16-19 November 2021 in London.

 

A webcast of the fireside chat will be available on the Jefferies conference portal and the replay will be available afterwards on the Investor Relations section of Arix's website here.

 

ENDS

 

Enquiries

 

For more information on Arix, please contact:

Arix Bioscience plc
+44 (0) 20 7290 1050
ir@arixbioscience.com

 

Optimum Strategic Communications

Mary Clark, Manel Mateus
+44 (0)20 8078 4357
optimum.arix@optimumcomms.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 


ISIN:

GB00BD045071

Category Code:

MSCM

TIDM:

ARIX

LEI Code:

213800OVT3AHQCXNIX43

OAM Categories:

3.1. Additional regulated information required to be disclosed under the laws of a Member State

Sequence No.:

126161

EQS News ID:

1246669


 

End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting